{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:00:10Z","timestamp":1773284410856,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":1497,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:p><jats:bold>Study Objective.<\/jats:bold> To assess the effect of daptomycin compared with vancomycin on the clinical and economic outcomes in patients with complicated skin and skin structure infections.<\/jats:p><jats:p><jats:bold>Design.<\/jats:bold> Prospective, open\u2010label study.<\/jats:p><jats:p><jats:bold>Setting.<\/jats:bold> Level 1 trauma center in Detroit, Michigan.<\/jats:p><jats:p><jats:bold>Patients.<\/jats:bold> Fifty\u2010three adult patients with complicated skin and skin structure infections at risk for methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) infection who were treated with daptomycin and a matched cohort of 212 patients treated with vancomycin.<\/jats:p><jats:p><jats:bold>Intervention.<\/jats:bold> Patients in the prospective arm received intravenous daptomycin 4 mg\/kg every 24 hours for at least 3 days but not more than 14 days. Historical controls received at least 3 days of vancomycin dosed to achieve trough concentrations of 5\u201320 \u03bcg\/ml.<\/jats:p><jats:p><jats:bold>Measurements and Main Results.<\/jats:bold> Outcomes evaluated included blinded assessments of clinical resolution, duration of therapy, and costs. The most common diagnoses were cellulitis (31%), abscess (22%), and both cellulitis with abscess (37%). Microbiology differed significantly between groups, with <jats:italic>S. aureus<\/jats:italic> found in 27 patients (51%) in the daptomycin group and 167 patients (79%) in the vancomycin group and MRSA in 22 (42%) and 159 (75%), respectively (p&lt;0.001). The proportions of patients with clinical improvement or resolution of their infections on days 3 and 5 were 90% versus 70% and 98% versus 81% in the daptomycin versus vancomycin groups, respectively (p&lt;0.01 for both comparisons), and 100% at the end of therapy in both groups. Among patients with complete resolution of their infections (41 patients [77%] with daptomycin vs 89 patients [42%] with vancomycin, p&lt;0.05), median duration of intravenous therapy was 4 and 7 days, respectively, (p&lt;0.001), and hospital costs were $5027 and $7552 (p&lt;0.001).<\/jats:p><jats:p><jats:bold>Conclusions.<\/jats:bold> Patients receiving daptomycin achieved more rapid resolution of symptoms and clinical cure and had a decreased duration of inpatient therapy compared with those receiving vancomycin. This study suggests that daptomycin is a cost\u2010effective alternative to vancomycin for complicated skin and skin structure infections.<\/jats:p>","DOI":"10.1592\/phco.27.12.1611","type":"journal-article","created":{"date-parts":[[2007,11,27]],"date-time":"2007-11-27T09:17:38Z","timestamp":1196155058000},"page":"1611-1618","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Daptomycin versus Vancomycin for Complicated Skin and Skin Structure Infections: Clinical and Economic Outcomes"],"prefix":"10.1002","volume":"27","author":[{"given":"Susan L.","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy S.","family":"McKinnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levi M.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"George","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Rybak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"Centers for Disease Control and Prevention National Center for Health Statistics.National hospital discharge survey. Available fromhttp:www.cdc.govnchsaboutmajorhdasdnhdstab.htm. Accessesd September 9 2006."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02311-06"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/501641"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/367653"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G728"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(03)00119-6"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/420818"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/502269"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.4.257.30933"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/313461"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.10.5026-5033.2005"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055356"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/507918"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/425009"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/381972"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/502522"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.27.12.1611","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.27.12.1611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:28:43Z","timestamp":1761046123000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.27.12.1611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1592\/phco.27.12.1611"],"URL":"https:\/\/doi.org\/10.1592\/phco.27.12.1611","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}